Yang Lyu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yang Lyu has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Angela C. Hirbe
Washington University School of Medicine
84 shared publications - Dana C. Borcherding
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
82 shared publications - Kevin He
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
82 shared publications - Xiaochun Zhang
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
82 shared publications - Christine A. Pratilas
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA
75 shared publications - Angad Gothra
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
74 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S10. Treatment with deucravacitinib and/or mirdametinib did not decrease mouse body weight over time.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S10. Treatment with deucravacitinib and/or mirdametinib did not decrease mouse body weight over time.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S6. TYK2 inhibition decreases expression of STAT3 target genes and increases expression of genes in the MEK/MAPK signaling cascade in MPNST cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S6. TYK2 inhibition decreases expression of STAT3 target genes and increases expression of genes in the MEK/MAPK signaling cascade in MPNST cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S5. Validation of select gene expression changes with TYK2 inhibitor treatment that were identified by qPCR array. JH-2-002 cells were incubated with 40 µMWU-12 or control for 48 hours, and gene expression was analyzed by qPCR for select(A)up-regulated or(B)down-regulated genes.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S5. Validation of select gene expression changes with TYK2 inhibitor treatment that were identified by qPCR array. JH-2-002 cells were incubated with 40 µMWU-12 or control for 48 hours, and gene expression was analyzed by qPCR for select(A)up-regulated or(B)down-regulated genes.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S4. TYK2 knockout decreases proliferation of MPNST-724 cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S4. TYK2 knockout decreases proliferation of MPNST-724 cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S1. Inhibition of TYK2 induces apoptosis in MPNST cell-lines
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S1. Inhibition of TYK2 induces apoptosis in MPNST cell-lines
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S9. Synergy of TYK2 and MEK inhibitors in MPNST-724 cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S9. Synergy of TYK2 and MEK inhibitors in MPNST-724 cells.